Search Results

and at the University in Graz in Austria, Maria worked several years at Novo Nordisk before joining InterAx Biotech in Switzerland as their Chief Scientific Officer. Maria Waldhoer on the web LinkedIn InterAx Biotech Pubmed Dr.

He is Chief Scientific Officer and co-founder of InterAx Biotech, where he specializes in the development Aurélien Rizk on the web InterAx Biotech Paul Scherrer Institut The Org LinkedIn Google Scholar Dr. They wrapped up the conversation by discussing job opportunities at Interax Biotech and their anticipation Aurelien Rizk, a co-founder and CEO of Interax Biotech, shared about the company's development of a discovery The discussion concluded with a brief overview of job opportunities at Interax Biotech, with Aurelien

I developed G.CLIPS biotech's innovative technology as a synthesis of the different knowledge, experiences Before founding G.CLIPS biotech in June 2020. GPCR Ecosystem G.CLIPS Biotech on the web Website LinkedIn Thanks for listening to this podcast episode

Kevin to chat about GPCRs, pharmacology, and his contributions to the field in both the academic and biotech Personalised Therapeutics Technologies, Chief Scientific Advisor to Dimerix, and co-founder of RAGE Biotech Experimental Pharmacologists and Toxicologists and is a member of the British Pharmacological Society International

After switching to biotech, Murat has built cell imaging software and lab robots to accelerate cancer He has co-founded consultancy and biotech companies Svarlight and Antiverse. start-up and in 5 years was responsible for project R&D and managing a focused development team, pursued international

led to the development and application of light energy transfer methodology to study protein-protein interaction He is the scientific founder of two biotech companies, ModMab Therapeutics , and AntlerA Therapeutics

GPCR Ecosystem, with the goal is to bring together GPCR scientists, biotech, and pharma leaders as well

More broadly, I hope to be a critical contributor to a growing Canadian biotech sector in both scientific

Annette worked in industry, academia and her entrepreneurial side led her to three companies, Cue Biotech

Inoviem scientific in Nov. 2011 by myself we have been regularly working with GPCRs for our pharma and biotech

As an industry pharmacologist, he consults with numerous pharma and biotechs in understanding and applying

neuroscience R&D program with Servier (France) and is the co-founder and CEO of Phrenix Therapeutics, a biotech Prior to these roles this he was Head of Pharmacology at Heptares Therapeutics Ltd., a UK-based biotechnology

pharmacologist with a ~30 years background in academia and industry, working both in big pharma and biotech at Novo Nordisk A/S allowed me to shape a swiss start-up company from a scientifc idea to a thriving Biotech Trejo has presented her studies at 52 national/international meetings and 66 academic seminars across

He consults with numerous pharmaceutical, biotech, life science and academic organizations in understanding

She received her undergraduate degree in Biotechnology from KIIT University in India. his expertise to enhance healthcare outcomes and contribute to the growth of the pharmaceutical and biotech of Pharmaceutical Sciences, Monash University, with a deep interest in understanding drug-receptor interactions

He has received substantial, long-term support from international and national competitive, charitable and commercial sources, as well as being academic co-founder of three GPCR-focussed biotechnology companies Professor Christopoulos has over 360 publications, including in leading international journals such as He has served on the Editorial Board of 8 international journals and was a Councillor of the International his experiences in the pharmaceutical industry, highlighting the differences between big pharma and biotech

< GPCR News < GPCRs in Oncology and Immunology Purinergic GPCR-integrin interactions drive pancreatic strategies we demonstrate mechanistically that this ATP-driven invasion requires direct protein-protein interactions Moreover, receptor-integrin interactions were required for effective downstream signalling, leading to This work elucidates a novel GPCR-integrin interaction in cancer invasion, highlighting its potential

About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Interaction

Everyone is welcome to present their work (students, postdocs, PI's, biotech, pharma companies)!

< GPCR News < GPCRs in Oncology and Immunology In Silico Design of Novel RGS2-Galpha-q Interaction Inhibitors Whole cell assays showed the top 10 ranking compounds, AJ-1-AJ-10, to inhibit RGS2-Gαq interactions.

: RAMP-interacting GPCR Pathways Date & Time Thursday, November 2nd / 4:30 PM Keynote Talk Abstract Coming

Signaling Read More GPCR Industry News December 12, 2024 Transforming Drug Discovery: Insights from Viva Biotech's

is an online platform that provides to (i) individuals and businesses such as scientists, students, biotech others with access to advertise, to promote, and market their services and products related to the biotech Either party in this agreement may seek any interim or preliminary relief from a court of competent jurisdiction

protein-coupled receptors: A target for microbial metabolites and a mechanistic link to microbiome-immune-brain interactions Published date October 1, 2023 Abstract "Human-microorganism interactions play a key role in human health readout of microbe-microbe-human relationship are of great interest for deeper understanding of the inter-kingdom modulate a range of human physiological functions, offering a mechanistic insight into the microbe-human interaction properties and blood-brain barrier permeability of the small-molecules we elucidated their molecular interactions

< GPCR News < GPCRs in Oncology and Immunology GPR176 Promotes Cancer Progression by Interacting with

He has received substantial, long-term support from international and national competitive, charitable and commercial sources, as well as being academic co-founder of three GPCR-focussed biotechnology companies Professor Christopoulos has over 360 publications, including in leading international journals such as He has served on the Editorial Board of 8 international journals and was a Councillor of the International They also emphasized the significance of fundamental discoveries, the role of biotech, and the need for

He has received substantial, long-term support from international and national competitive, charitable and commercial sources, as well as being academic co-founder of three GPCR-focussed biotechnology companies Professor Christopoulos has over 360 publications, including in leading international journals such as He has served on the Editorial Board of 8 international journals and was a Councillor of the International They also emphasized the significance of fundamental discoveries, the role of biotech, and the need for

and John had a detailed discussion about the prospects of staying in academia versus transitioning to biotech